Serina Therapeutics, INC Form 4 insider transactions

Jay Venkatesan, a director of Serina Therapeutics, acquired 40,000 stock options on February 12, 2025.

Juvenescence Ltd, a significant shareholder in Serina Therapeutics, executed warrant exercises and stock purchases, increasing its holdings in the company.

Karen J. Wilson, a director of Serina Therapeutics, Inc., acquired stock options for 40,000 shares on January 14, 2025.

Director Gregory Bailey of Serina Therapeutics acquired 3,866 shares of common stock in a series of open market transactions.

Director Gregory Bailey of Serina Therapeutics, Inc. (SER) purchased 1,137 shares of common stock at an average price of $6.0259 on September 20, 2024.

Director Gregory Bailey acquired additional shares of Serina Therapeutics (SER) in two transactions on September 18 and 19, 2024.

Director Steven Mintz reports purchasing 6,000 shares of Serina Therapeutics at an average price of $6.469 on September 12, 2024.

Serina Therapeutics CEO Steven Ledger reports acquisition of stock options and disposal of shares.

Director Gregory Bailey of Serina Therapeutics, Inc. recently purchased 1,776 shares of common stock at an average price of $8.25.

Gregory S. Curhan, CFO of Serina Therapeutics, Inc., reports the acquisition of stock options in the company.

Director Gregory Bailey reports purchasing additional shares of Serina Therapeutics (SER) in a series of transactions.

Director Steven Mintz reports purchasing additional shares of Serina Therapeutics, Inc. at an average price of $6.5893 on August 15, 2024, through both direct and indirect ownership.

Gregory Bailey, a director of Serina Therapeutics, Inc., reported purchasing 6,400 shares of common stock at an average price of $7.0669 per share on August 14, 2024.

Srini Tenjarla, SVP, CMC & Formulation at Serina Therapeutics, acquired 185,000 stock options on July 15, 2024.

Director Steven Mintz reports acquisition and disposal of Serina Therapeutics (SER) common stock.

Director Gregory Bailey of Serina Therapeutics, Inc. reports purchasing common stock in two transactions on May 29 and May 30, 2024.

Gregory Bailey, a director at Serina Therapeutics, recently engaged in transactions involving the company's common stock, acquiring 9,019 shares and disposing of 13,828 shares on May 28, 2024.

Director Gregory Bailey reported purchasing shares of Serina Therapeutics (SER) on May 21 and May 23, 2024.

Director Steven Mintz reports multiple purchases of Serina Therapeutics (SER) common stock through indirect ownership.

Director Gregory Bailey of Serina Therapeutics, Inc. reports purchasing 1,422 shares of common stock at $9.50 per share on May 21, 2024.

Gregory Bailey, a director of Serina Therapeutics, reported the acquisition and disposal of 100 shares of common stock on May 20, 2024.

Director Simba Gill acquired 295,300 stock options in Serina Therapeutics on April 15, 2024.

Director Gregory Bailey reports acquisition of stock options in Serina Therapeutics.

Director Steven Mintz reports acquisition of stock options in Serina Therapeutics.

Director Richard Peter Marshall acquired 40,000 stock options in Serina Therapeutics on April 1, 2024.

Director J Milton Harris acquired 40,000 stock options in Serina Therapeutics on April 1, 2024.

Director Remy Gross acquired 40,000 stock options in Serina Therapeutics on April 1, 2024, according to a Form 4 filing.

AgeX Therapeutics drew $500,000 from its existing credit facility, declared a warrant dividend related to the Serina Therapeutics merger, and provided updates on the merger's progress, including a reverse stock split.